Clinical Trial Update: A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of idasanutlin in combination with obinutuzumab for relapsed/refractory follicular lymphoma and with rituximab for relapsed/refractory DLBCL; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Idasanutlin (Idasanutlin)
• Obinutuzumab (obinutuzumab)
• Rituximab (rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Hodgkin's Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-04-29